12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

Affinity Equity Partners, the private equity firm that acquired South Korea’s two largest rental car companies, is securing 1 ...

The Town of Leader held its regular council meeting on January 7, with Mayor Aaron Wenzel and Councillors Dustin Heatcoat, ...

Commerce Adviser SK Bashir Uddin has not yet received a copy of the task force report on re-strategising the economy, despite ...

South Korea's central bank on Tuesday slashed interest rates and its annual growth forecast as it looks to bolster the ...

Together AI has raised $305 million in its Series B funding round. Self-described as an AI acceleration cloud, Together AI's funding round was led by General Catalyst, and co-led by Prosperity7, with ...